share_log

Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling

Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling

Moderna、再生元製藥公司和其他2只股票的內部人士正在拋售
Benzinga ·  07/15 08:19

The Nasdaq 100 closed higher by more than 100 points on Friday. Investors, meanwhile, focused on some notable insider trades.

納斯達克100指數週五收盤上漲超過100點。與此同時,投資者們關注了一些著名的內部交易。

When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.

當內部人士出售股份時,可能是預先計劃好的賣出,也可能表明他們對公司前景的擔憂,或者認爲股票價格過高。內部人士的賣出不應被視爲制定投資或交易決策的唯一指標。充其量,它可以加強賣出決策的信心。

Below is a look at a few recent notable insider sales. For more, check out Benzinga's insider transactions platform.

以下是最近一些值得注意的內部交易。了解更多,請查看Benzinga的內部交易平台。

DICK'S Sporting Goods

迪克體育用品

  • The Trade: DICK'S Sporting Goods, Inc. (NYSE:DKS) Director Desiree Ralls-Morrison sold a total of 3,489 shares at an average price of $206.65. The insider received around $721,002 from selling those shares.
  • What's Happening: On May 29, Dick's Sporting Goods reported better-than-expected first-quarter FY24 earnings and raised the outlook.
  • What DICK'S Sporting Goods Does: Dick's Sporting Goods retails athletic apparel, footwear, and equipment for sports.
  • 交易:紐交所迪克體育用品股份有限公司(DKS)董事Desiree Ralls-Morrison以平均價格206.65美元出售了共計3489股。內部人士從出售這些股份中獲得了大約721,002美元的收益。
  • 正在發生的事情:5月29日,迪克體育用品公佈了超出預期的2024財年第一季度收益,並提高了前景。
  • 迪克體育用品主要零售體育運動服裝、鞋類和器材。

Have a look at our premarket coverage here

在此查看我們的盤前報道

Regeneron Pharmaceuticals

再生元製藥公司

  • The Trade: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP General Counsel and Secretary Joseph J Larosa sold a total of 1,866 shares at an average price of $1,088.95. The insider received around $2.03 million from selling those shares.
  • What's Happening: On July 11, Morgan Stanley analyst Matthew Harrison maintained Regeneron Pharmaceuticals with an Overweight and lowered the price target from $1,183 to $1,182.
  • What Regeneron Pharmaceuticals Does: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation.
  • 交易:納斯達克再生元製藥股份有限公司(REGN)執行副總裁兼秘書Joseph J Larosa以平均價格1088.95美元出售了共計1866股。內部人士從出售這些股份中獲得了大約203萬美元的收益。
  • 正在發生的事情:7月11日,摩根士丹利分析師Matthew Harrison維持對再生元製藥的股票推薦爲“買入”,但將價格目標從1183美元下調至1182美元。
  • 再生元製藥公司的主要業務是開發和商業化對抗眼疾、心血管疾病、癌症和炎症的產品。

SMART Global Holdings

智能環球控股

  • The Trade: SMART Global Holdings, Inc. (NASDAQ:SGH) President, LED Solutions Joseph Gates Clark sold a total of 5,000 shares at an average price of $29.00. The insider received around $145,006 from selling those shares.
  • What's Happening: On July 9, SMART Global reported better-than-expected third-quarter financial results.
  • What SMART Global Does: SMART Global Holdings Inc is a designer and manufacturer of electronic products focused on memory and computing technology areas.
  • 交易:納斯達克智能環球控股股份有限公司(SGH)LED解決方案總裁Joseph Gates Clark以平均價格29.00美元出售了共計5000股。內部人士從出售這些股份中獲得了大約145,006美元的收益。
  • 正在發生的事情:7月9日,智能環球公佈了超出預期的第三季度財務業績。
  • 智能環球控股公司是一家電子產品設計和製造公司,專注於存儲和計算技術領域。

Moderna

Moderna

  • The Trade: Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan sold a total of 15,000 shares at an average price of $117.08. The insider received around $1.8 million from selling those shares.
  • What's Happening: Moderna is expected to report its second quarter financial results on Thursday, Aug. 1.
  • What Moderna Does: Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018.
  • 交易:納斯達克Moderna股份有限公司(MRNA)董事Noubar Afeyan以平均價格117.08美元出售了共計15000股。內部人士從出售這些股份中獲得了大約180萬美元的收益。
  • 正在發生的事情:Moderna預計於8月1日星期四公佈其第二季度財務業績。
  • Moderna是一家商業化生物科技公司,成立於2010年,於2018年12月首次公開募股。
  • How To Earn $500 A Month From Bank of America Stock Ahead Of Q2 Earnings
  • 如何在美國銀行股份二季度收益發布前每月賺取500美元
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論